...
首页> 外文期刊>Annals of Oncology >Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer
【24h】

Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer

机译:细胞减灭术和术中加热腹腔内化学疗法治疗原发性和复发性卵巢癌腹膜癌的系统评价

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this systematic review is to critically evaluate cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy in the treatment of ovarian cancer. A systematic review of all manuscripts published in the English literature that met predetermined inclusion criteria was carried out. Data concerning cytoreductive surgery, method and agents for administration of heated intraoperative intraperitoneal chemotherapy, morbidity, mortality, hospital stay and survival were extracted, critically reviewed and tabulated. Fourteen studies were analyzed. A wide variety of drug doses, methods of intraperitoneal chemotherapy administration and volume of chemotherapy solution were used. Seven studies showed that patients with complete cytoreduction had the greatest benefit. The median overall survival for primary and recurrent disease ranged from 22 to 54 months and the median disease-free survival from 10 to 26 months. The rates of significant morbidity associated with this combined treatment were low, ranging from 5% to 36%. The median mortality was 3% (range 0%–10%). Cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy is a treatment option for patients with ovarian cancer that is worthy of further investigation. Selection criteria for patients most likely to benefit need to be defined.
机译:该系统评价的目的是严格评估细胞减灭术联合加热的术中腹膜内化疗治疗卵巢癌的可能性。对英语文献中符合预定纳入标准的所有手稿进行了系统评价。提取有关细胞减灭术,术中加热腹腔内化疗的方法和药物,发病率,死亡率,住院时间和生存率的数据,进行严格审查并制成表格。分析了十四项研究。使用了各种各样的药物剂量,腹膜内化疗方法和化疗溶液体积。七项研究表明,完全细胞减少的患者获益最大。原发性和复发性疾病的中位总生存期为22到54个月,无病生存期的中位生存期为10到26个月。与这种联合治疗相关的显着发病率很低,从5%到36%不等。中位死亡率为3%(范围为0%-10%)。细胞减少术联合加热的术中腹膜内化疗是卵巢癌患者的治疗选择,值得进一步研究。需要确定最有可能受益的患者的选择标准。

著录项

  • 来源
    《Annals of Oncology》 |2007年第12期|1943-1950|共8页
  • 作者单位

    Peritoneal Surface Malignancy Program Washington Cancer Institute Washington DC;

    Department of Women's Services Washington Hospital Center Washington DC USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号